The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know ...

Novo Nordisk, which is owned by Novo Holdings, will directly purchase the Bloomington location and two other fill-finish sites in Europe from its parent company. Catalent, a third-party manufacturer ...

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity ... Brussels in Belgium, and Bloomington, ...

Phil Powell, Indiana University professor of business economics, led off remarks on Wednesday with three statistics that he ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...